DUBLIN, August 12. 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "NHL: Diffuse Large Bcell Lymphoma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.
An increase in disease prevalence and the launch of new targeted therapies across a range of treatment settings will drive the growth of the diffuse large B-cell lymphoma (DLBCL) market during 2016-25 despite Rituxan's patent expiry.
This report addresses the following questions:
- What will drive the growth of the DLBCL market during 2016-25?
- Which geographical market will be the most lucrative and which will experience the fastest growth?
- Which branded therapies will have the largest impact on the DLBCL market?
- Which therapies will target patient populations that represent unmet needs in DLBCL?
- When will generic and biosimilar therapies enter the market and what impact will they have on revenues?
Key Topics Covered:
FORECAST: DIFFUSE LARGE B-CELL LYMPHOMA
- Market Overview and Trends
- Market Definition and Methodology
- Afinitor (everolimus)
- Biosimilar rituximab
- Gazyva (obinutuzumab)
- Imbruvica (ibrutinib)
- Revlimid (lenalidomide)
- Rituxan (rituximab)
- Velcade (bortezomib)
- Primary Research Methodology
TREATMENT: DIFFUSE LARGE B-CELL LYMPHOMA
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
EPIDEMIOLOGY: DIFFUSE LARGE B-CELL LYMPHOMA
- Disease Background
- Sources and Methodology
- Forecast: NHL Overall
- Forecast: NHL Subtypes (incl. DLBCL, FL, and MCL)
- Epidemiologist Insight
- Strengths and Limitations
MARKETED DRUGS: DIFFUSE LARGE B-CELL LYMPHOMA
- Product Overview
- Product profile: Rituxan
PIPELINE: DIFFUSE LARGE B-CELL LYMPHOMA
- Clinical Pipeline Overview
- Target Product Profile
- Recently Discontinued Drugs
- Product profile (late stage): Afinitor
- Product profile (late stage): Gazyva
- Product profile (late stage): Imbruvica
- Product profile (late stage): Keytruda
- Product profile (late stage): Revlimid
- Product profile (late stage): Velcade
For more information about this report visit http://www.researchandmarkets.com/research/ckjmbr/nhl_diffuse
Related Topics: Lymphoma Drugs
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article